Home > News > European Patent Granted
September 2nd, 2004
European Patent Granted
Abstract:
Global nanotechnology company pSivida Limited, is pleased to announce that its UK operating subsidiary pSiMedica Limited has been granted a further European patent for BioSilicon™. European Patent Number 1220659 relates to the invention of orally administrable pharmaceutical products (eg tablets, capsules, pellets and powders) that comprise porous and/or polycrystalline silicon (BioSilicon™). Oral administration of drugs remains the most favoured route of treatment, being painless and enabling the patient to self-administer. BioSilicon™, allows drug molecules to be held in nanosized pockets that release tiny pulses of drug as the BioSilicon™ dissolves.
Source:
pSivida
Related News Press |
Nanomedicine
New micromaterial releases nanoparticles that selectively destroy cancer cells April 5th, 2024
Good as gold - improving infectious disease testing with gold nanoparticles April 5th, 2024
Researchers develop artificial building blocks of life March 8th, 2024
Announcements
NRL charters Navy’s quantum inertial navigation path to reduce drift April 5th, 2024
Discovery points path to flash-like memory for storing qubits: Rice find could hasten development of nonvolatile quantum memory April 5th, 2024
Patents/IP/Tech Transfer/Licensing
Getting drugs across the blood-brain barrier using nanoparticles March 3rd, 2023
Metasurfaces control polarized light at will: New research unlocks the hidden potential of metasurfaces August 13th, 2021
Arrowhead Pharmaceuticals Announces Closing of Agreement with Takeda November 27th, 2020
The latest news from around the world, FREE | ||
Premium Products | ||
Only the news you want to read!
Learn More |
||
Full-service, expert consulting
Learn More |
||